

Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
You can purchase shares of Revelation Biosciences (NASDAQ:REVB) through any online brokerage.
Other companies in Revelation Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
There is no analysis for Revelation Biosciences to provide a consensus price target.
The stock price for Revelation Biosciences (NASDAQ: REVB) is $3.6323 last updated November 6, 2026 at 10:10 AM EST.
There are no upcoming dividends for Revelation Biosciences.
Revelation Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Revelation Biosciences.
Revelation Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is...